Race-related differences in heart failure therapies: Simply black and white or shades of grey?

Current Cardiology Reports

Volumn 9, Issue 3, 2007, Pages 178-181

  Shroff, Gautam R ^b   Taylor, Anne L ^b   Colvin Adams, Monica ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; METOPROLOL; NITRIC OXIDE SYNTHASE; PLACEBO; PRAZOSIN;

AFRICAN AMERICAN; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESEARCH; ETHNIC DIFFERENCE; GENETIC VARIABILITY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HISPANIC; HOSPITALIZATION; HUMAN; HYPERTENSION; META ANALYSIS; MORTALITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PREVALENCE; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SYSTEMATIC REVIEW;

AFRICAN AMERICANS; CLINICAL TRIALS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 34249110642     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02938347     Document Type: Review

References (29)

1. Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in African Americans with heart failure. N Engl J Med 2004, 351:2049-2057.
2. Rosamond W, Flegal K, Friday G, et al., for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart Disease and Stroke Statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69-e171.
3. Laditka JN, Laditka SB: Race, ethnicity and hospitalization for six chronic ambulatory care sensitive conditions in the USA. Ethn Health 2006, 11:247-263.
4. Deswal A, Peterson NJ, Urbauer DL, et al.: Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. Am Heart J 2006, 152:348-354.
5. Matthew J, Wittes J, McSherry F, et al.: Racial differences in outcome and treatment effect in congestive heart failure. Am Heart J 2005, 150:968-976.
6. Singh H, Gordon HS, Deswal A: Variation by race in factors contributing to heart failure hospitalizations. J Cardiac Fail 2005, 11:23-29.
7. Gillum RF: The epidemiology of cardiovascular disease in African American Americans. N Engl J Med 1996, 335:1597-1599.
8. Dries DL, Exner DV, Gersh BJ, et al.: Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999, 340:609-616.
9. Exner DV, Dries DL, Domanski MJ, et al.: Lesser response to angiotensin-converting-enzyme inhibitor therapy in African American as compared with white patients with left ventricular dysfunction. N Engl J Med 2001, 344:1351-1357.
10. Dunlap SH, Mallemala S, Sueta CA, et al.: Survival rates are similar between African American and white patients with heart failure. Am Heart J 2003, 146:265-272.
11. Echols MR, Felker GM, Thomas KL, et al.: Racial differences in the characteristics of patients admitted with acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. J Cardiac Fail 2006, 12:684-688.
12. Hall WD: Representation of African Americans, women, and the very elderly (aged > 80) in 28 major randomized clinical trials. Ethn Dis 1999, 9:333-340.
13. Cohn JN, Archibald DG, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 314:1547-1552.
14. Carson P, Ziesche S, Johnson G, Cohn JN: Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999, 5:178-187.
15. Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
16. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
17. Anand IS, Tam WS, Rector TS, et al.: Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African American Heart Failure trial. J Am Coll Cardiol 2007, 49:32-39.
18. Yancy CW: Heart failure in African Americans. Am J Cardiol 2005, 96(Suppl):3i-12i.
19. Rudic RD, Sessa WC: Nitric oxide in endothelial dysfunction and vascular remodeling: clinical correlates and experimental links. Am J Hum Genet 1999, 64:673-677.
20. Scherrer-Crosbie M, Ullrich R, Bloch KD, et al.: Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001, 104:1286-1291.
21. Kaliniowki L, Dobrucki I, et al.: Race-specific differences in endothelial function: predisposition of African Americans to vascular disease. Circulation 2004, 109:2511-2517.
22. Houghton JL, Smith VE, Strogatz DS, et al.: Effect of African American race and hypertensive left ventricular hypertrophy on coronary vascular reactivity and endothelial function. Hypertension 1997, 29:706-714.
23. Vivian EM: Should drug therapy be personalized based on race ? Ann Pharmacother 2006, 40:550-552.
24. McNamara DM, Tam SW, Sabolinski M, et al.: Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT trial. J Am Coll Cardiol 2006, 48:1277-1282.
25. Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): ACC/ AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005, 46:e1-e82.
26. Wallace TW, Drazner MH: The impact of race on response to RAAS inhibition. Curr Heart Fail Rep 2005, 2:72-77.
27. Shekelle PG, Rich MW, Morton SC, et al.: Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41:1529-1538.
28. Beta-Blocker Evaluation of Survival Trial Investigators: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344:1659-1667.
29. Yancy CW, Fowler MB, Colucci WS, et al.: Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001, 344:1358-1365.